Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis.
about
Delta-aminolevulinic acid cytotoxic effects on human hepatocarcinoma cell linesDrug Carrier for Photodynamic Cancer TherapyNovel endoscopic diagnosis for bladder cancerThe photodynamic and non-photodynamic actions of porphyrins.Effects on the mitosis of normal and tumor cells induced by light treatment of different wavelengths.Metal-assisted red light-induced efficient DNA cleavage by dipyridoquinoxaline-copper(II) complex.Development of a fluorescence detection system using optical parametric oscillator (OPO) laser excitation for in vivo diagnosis.Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source.Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot studyMelatonin protects against oxidative stress caused by delta-aminolevulinic acid: implications for cancer reduction.New optical technologies for earlier endoscopic diagnosis of premalignant gastrointestinal lesions.Optical diagnostics in urology: current applications and future prospects.In vitro studies on the potential use of 5-aminolaevulinic acid-mediated photodynamic therapy for gynaecological tumours.Photodynamic diagnosis with 5-aminolevulinic acid for intraoperative detection of peritoneal metastases of ovarian cancer: A feasibility and dose finding study.Delta-aminolaevulinic acid-induced photodynamic therapy inhibits protoporphyrin IX biosynthesis and reduces subsequent treatment efficacy in vitro.Laser-induced fluorescence studies of normal and malignant tumour tissue of rat following intravenous injection of delta-amino levulinic acid.Comparative study of the interaction of meso-tetrakis (N-para-trimethyl-anilium) porphyrin (TMAP) in its free base and Fe derivative form with oligo(dA.dT)15 and oligo(dG.dC)15.Dye Sensitizers for Photodynamic TherapyEffects of diabetes mellitus on patients with acute intermittent porphyria.Acute hepatic porphyria and cancer risk: a nationwide cohort study.Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model.Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes.Relevance of cytochrome P450 levels in the actions of enflurane and isoflurane in mice: studies on the haem pathway.High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria.Inhibition of 5-aminolevulinic acid-induced DNA damage by melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine, quercetin or resveratrol.Theoretical model for optical properties of porphyrin.Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden.Study of protoporphyrin IX (PpIX) pharmacokinetics after topical application of 5-aminolevulinic acid in urethral condylomata acuminata.Detection of early stages of carcinogenesis in adenomas of murine lung by 5-aminolevulinic acid-induced protoporphyrin IX fluorescence.
P2860
Q24806056-5DECCCDE-1063-40C7-B002-4FFFDF4B3D0DQ26782780-AC0B9D45-5ECC-4A2C-BAC3-481BD670649BQ26828949-9136FC6E-2D99-4B7D-A2C9-B034AFF6F03DQ30322731-4A97D110-59B1-4B25-AE93-FE064B1ADAA7Q30777878-7AE9E8F5-6A92-40D6-AAFB-01904F28A7B2Q31020238-0C83C956-694F-40AB-936B-BFE64A51040EQ33195399-711B657D-B84C-4F37-8FC9-F9A2A3882894Q34190458-0087EBDF-83C8-4438-A6C5-FC8EE87968F0Q34407455-613E7CEE-628D-488A-8BAF-CF60A5FDCB0DQ34569017-6805A01D-7623-4DF6-B97F-7B2D9F0F3DEFQ34631355-39D80650-AC71-4659-9C4C-94CFDD25FEC5Q35203921-0A15324B-52F9-4EEC-A4FF-778A31D1C93EQ36136168-DB843D35-7520-4FE8-84DE-6076629EA81CQ36196629-B40985C9-158E-414E-B3DC-5AB014E6B977Q36620285-ED7B8E66-0D82-4607-99BD-3C2016CC077BQ36858801-1480F662-EE93-4CE0-BCC4-9EE415FA811BQ38303802-D649CBE4-DB3D-470C-B48F-51C54717C926Q38624133-A8B9F853-4C53-46D3-A429-6393ADFF96F5Q39440819-FD5D2A09-45B5-4657-A51E-AD7D6E2BE5CAQ40113705-B2B7136E-F7AC-455B-9AF3-6F3CE6BB07A9Q40606992-18A3E88D-3762-47D6-BAB3-07B83FA5FABFQ42090164-1225E8D0-ACAC-48BA-862C-FC7F49D18593Q43508022-D78505F5-EFE0-460F-92FC-DCB1D7D33A57Q44671694-67C8B44A-56F1-4909-85C1-27414F492DF8Q45245847-CE82205E-4C86-4C83-9CD2-8C460EFA2305Q50282943-4FACFB47-52A7-4C94-84D3-868F3850F7D7Q51156863-CEE80289-342F-4689-ABAF-599A42DDC1C2Q51736689-A0E864A8-B232-4B7C-86EB-ADB072F036B8Q53450950-6002C15A-6E57-47CF-B8A1-2C1BC3FF7824
P2860
Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis.
@en
type
label
Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis.
@en
prefLabel
Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis.
@en
P1476
Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis.
@en
P2093
P356
10.1016/1011-1344(93)80127-U
P577
1993-09-01T00:00:00Z